So many movie titles, so little time. A New Jersey law expected to go into effect next month raises the age when unmarried young adults are no longer covered under parents' insurance to 30 — the oldest in the nation.

Failure to Launch comes to mind, but then one finds that the young adults do not have to be living at home to qualify, nor do they have to be students. Maybe 13 Going on 30? Actually, the law covers 18 to 30.

"In New Jersey, our concern is that the law is so broad you do not have to be a student, you do not have to be a dependent, you do not have to live with your parents," says Susan Pisano, a spokeswoman for America's Health Insurance Plans. "All you have to be is 30, uninsured, and a resident of the state."

Is this a trend? While the Garden State is the outlier, USA Today reports that six other states have expanded coverage to those who are 24, 25, or 26 years of age. Those states are: Colorado, Illinois, New Mexico, South Dakota, Texas, and Utah.

USA Today reports: "Several other states, including Kentucky, Massachusetts, and New York, are considering similar measures. . . ."

Pisano says that AHIP members understand that these examples are attempts by policymakers to keep up with a changing society. There are a great number of people between 18 and 30 who are uninsured. Some take longer than the traditional four years to finish college, and there have been many articles in consumer publications about grown children who somehow make their way back to the nest.

"Our members understand what's going on and also made a contribution in the form of particular kinds of products that have lower premiums and are more portable for this age group," says Pisano. "Having said that, there are a number of states that have acted to change the definition of who is a dependent. The New Jersey law redefines dependent in a way that could potentially have a negative effect on others who are covered by the particular employer."

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.